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Introduction: Studies have demonstrated that mesenchymal stromal cells (MSCs) could reverse acute and chronic
kidney injury by a paracrine or endocrine mechanism, and microvesicles (MVs) have been regarded as a crucial
means of intercellular communication. In the current study, we focused on the therapeutic effects of human
Wharton-Jelly MSCs derived microvesicles (hWJMSC-MVs) in renal ischemia/reperfusion injury and its potential
mechanisms.
Methods: MVs isolated from conditioned medium were injected intravenously in rats immediately after ischemia
of the left kidney for 60 minutes. The animals were sacrificed at 24 hours, 48 hours and 2 weeks after reperfusion.
The infiltration of inflammatory cells was identified by the immunostaining of CD68+ cells. ELISA was employed to
determine the inflammatory factors in the kidney and serum von Willebrand Factor (VWF). Tubular cell proliferation
and apoptosis were identified by immunostaining. Renal fibrosis was assessed by Masson’s tri-chrome straining and
alpha-smooth muscle actin (α-SMA) staining. The CX3CL1 expression in the kidney was measured by immunostaining
and Western blot, respectively. In vitro, human umbilical vein endothelial cells were treated with or without MVs for 24
or 48 hours under hypoxia injury to test the CX3CL1 by immunostaining and Western blot.
Results: After administration of hWJMSC-MVs in acute kidney injury (AKI) rats, renal cell apoptosis was mitigated
and proliferation was enhanced, inflammation was also alleviated in the first 48 hours. MVs also could suppress the
expression of CX3CL1 and decrease the number of CD68+ macrophages in the kidney. In the late period, improvement
of renal function and abrogation of renal fibrosis were observed. In vitro, MVs could down-regulate the expression of
CX3CL1 in human umbilical vein endothelial cells under hypoxia injury at 24 or 48 hours.
Conclusions: A single administration of MVs immediately after ischemic AKI could ameliorate renal injury in both the
acute and chronic stage, and the anti-inflammatory property of MVs through suppression of CX3CL1 may be a potential
mechanism. This establishes a substantial foundation for future research and treatment.* Correspondence: lumujun@163.com; zhuyingjian_sjtu@126.com
†Equal contributors
5Department of Urology, Ninth People’s Hospital, School of Medicine,
Shanghai Jiao Tong University, Shanghai, P.R. China
1Department of Urology, Shanghai First People’s Hospital, School of
Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China
Full list of author information is available at the end of the article
© 2014 Zou et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Zou et al. Stem Cell Research & Therapy 2014, 5:40 Page 2 of 13
http://stemcellres.com/content/5/2/40Introduction
Ischemia/reperfusion (I/R) injury is a major cause of in-
trinsic acute kidney injury (AKI), which has emerged as
the most common condition in hospitalized patients and
continues to result in a high mortality rate [1]. Ischemia/
reperfusion injury (IRI)-induced AKI may result in pro-
liferation of fibroblasts and excessive deposition of extra-
cellular matrix [2] and has been recognized as a major
contributor to end-stage kidney disease [3]. Therefore,
a potent therapeutic intervention for ischemic AKI is
imperative.
Inflammation is now believed to play a major role in
the pathophysiology of AKI [1]. Various specific inflam-
matory cells and pro-inflammatory cytokines/chemo-
kines are increased in the kidney in the early phase of
injury after an ischemic AKI [4,5]. Among these inflam-
matory cells, a macrophage is an important mediator in
the initiation and extension of ischemic/reperfusion in-
jury [6,7]. The function of macrophages and inflamma-
tory cytokines in tissue repair at different stages is still
unclear. However, a previous publication showed that
strategies which limit the initial macrophage infiltration
or activation can be beneficial for ischemic AKI [8]. SJ
Yu et al. also found that macrophage depletion using
clodronate could protect against ischemic AKI [9]. Further
studies indicated that knockout or neutralizing against ad-
hesion molecule-1 in mice also prevents macrophage re-
cruitment and the expression of inflammatory cytokines,
which consequently induces less severe damage in renal
disease models [10,11]. The transmigration of macro-
phages across the vascular endothelium into tissues de-
pends upon the influence of various factors, including
adhesion molecules, chemokines and their receptors [12].
CX3CL1, also called fractalkine, is found mainly expressed
on endothelial cells and is a potent chemo-attractant fac-
tor for macrophages [13,14]. It has been reported that the
up-regulation of CX3CL1 was observed in I/R induced
AKI, and CX3CL1/CX3CR1 could promote kidney inter-
stitial fibrosis after IRI [15]. Meanwhile, inhibition of
CX3CR1 reduces the macrophages in the injured kidney
and has the effects of therapy in AKI [14,16]. These stud-
ies indicate that CX3CL1 is an important target molecule
in anti-inflammation therapy for ischemic AKI.
Although the kidney has been thought to have a cer-
tain capacity for self-repair or regeneration after ischemic
AKI, several strategies have been proposed to promote re-
covery from AKI. Among them, MSCs are thought of as a
promising and effective strategy to contribute to kidney
repair, although the mechanisms are not very clear now.
MSCs display an immune-modulatory activity which is
important in the response to tissue injury [17], and the in-
flammatory suppression role of MSCs in renal IRI was
also reported [18]. On the other hand, the paracrine or
endocrine mechanisms of MSCs in tissue injury repairhave also been proposed recently [19,20]. Microvesicles
(MVs) derived from MSCs are recently exploited in re-
generative medicine to repair damaged tissues. These
membranous structures delivering bioactive molecular
contents, such as proteins, mRNAs and micro-RNAs se-
quences, are described as a novel pathway in cell-to-cell
interaction. It has also been reported that MVs derived
from MSCs could protect AKI in I/R animal models
[21,22]. However, the real mechanisms are unclear and
whether the Wharton’s Jelly mesenchymal stromal cells
derived microvesicles (hWJMSC-MVs) could play an
immunomodulation role in ischemic AKI is unknown.
The objectives of the present study were to investigate
the possible therapeutic potential of hWJMSC-MVs to
rescue rats from AKI and to clarify the possible mecha-
nism(s) by which hWJMSC-MVs may improve renal
function in this ischemic AKI model.
Materials and methods
Cell culture
Fresh human umbilical cords that are usually discarded
after delivery were obtained with the written consent
of the parents. This experiment was approved by the
Research Ethics Committee at Shanghai First People’s
Hospital-affiliated Shanghai Jiao Tong University (Permit
number: 2013KY018). Human umbilical cords were de-
livered and stored in cold Hank’s balanced salt solution
(Sigma-Aldrich, St Louis, MO, USA) and then cellular iso-
lation started within 4 h. The hWJMSCs were isolated and
identified as described previously [23]. Briefly, with the
elimination of umbilical cord vessels, mesenchymal tissues
were cut into 1 mm3 pieces and then stuck to the sub-
strate of culture plates individually, followed by the addi-
tion of low-glucose Dulbecco, Modified Eagle’s Medium
(DMEM, Gibco BRL Co., USA) containing 10% fetal
bovine serum (FBS, Gibco BRL Co., USA) at 37°C in a hu-
midified atmosphere with 5% CO2. The medium was
changed every two days. After about two weeks’ cul-
ture, the adherent cells were harvested with 0.25% trypsin
(Gibco BRL Co., USA) treatment and sub-cultured. Only
cells from three to six passages were used for further
experiments.
Human umbilical vein endothelial cells (HUVEC) were
isolated from umbilical cord veins by collagenase di-
gestion. In brief, the veins were washed twice with
phosphate-buffered saline (PBS), and the HUVECs were
flushed out after digestion with 0.1% collagenase (Gibco
BRL Co., USA) for 30 minutes at room temperature.
HUVECs were seeded onto dishes in EGM-2 medium at
37°C in a humidified atmosphere with 5% CO2. The me-
dium was changed every two days. After one week’s cul-
ture, the adherent cells were harvested with 0.05% trypsin
(Gibco BRL Co., USA) treatment and sub-cultured. Only
cells from passages 2 to 4 were used for experiments.
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immunofluorescence using CD31 (Abcam, Cambridge,
UK) and VE- Cadherin (Abcam).
Isolation of MVs
MVs were obtained from supernatants of hWJMSCs as
was previously described [24]. Briefly, hWJMSCs were
cultured in DMEM without FBS and with added 0.5%
bovine serum album (BSA) (Sigma-Aldrich) overnight.
The viability of the cell cultured overnight was >99% as
detected by trypan blue exclusion and no apoptotic cells
were detected by terminal transferase-mediated dUTP
nick-end labeling (TUNEL) assay. The conditioned me-
dium was collected and stored at -80°C. The medium
was centrifuged at 2,000 g for 20 minutes to remove
debris, and then ultracentrifuged at 100,000 g in a SW41
swing rotor (Beckman Coulter, Fullerton, CA, USA) for
one hour at 4°C. MVs were washed once with serum-
free M199 (Sigma-Aldrich) containing 25 mM HEPES
(pH = 7.4) and submitted to a second ultracentrifugation
in the same conditions. MVs were stored at -80°C for
the experiments. To quantify the protein content, the
Bradford protein assay kit (P0006, Beyotime Institute of
Biotechnology, China) was used in the Bradford assay.
We quantified it indirectly according to 5 × 105 MSCs
releasing approximately 100 μg MVs overnight.
Transmission electron microscopy
MVs were fixed with 2.5% glutaraldehyde in PBS for 2 h,
after being washed; MVs were ultra-centrifuged and sus-
pended in 100 uL PBS. A total of 20 uL of MVs was loa-
ded onto a formvar/carbon-coated grid, negatively stained
with 3% aqueous phosphor-tungstic acid for one mi-
nute and observed by transmission electron micros-
copy (HITACHI, H-7650, Japan).
MVs surface marker analysis
Flow cytometry was used to characterize the isolated
MVs. MVs were incubated for 30 minutes at room tem-
perature, 5 ml of latex beads were added and incubated
for another 30 minutes at 4°C, then washed in 0.5% BSA
in PBS and incubated with different antibodies (CD9,
CD34, CD44, CD45, CD63, CD73 or with appropriate
isotype control IgG. After washing, MV-coated beads were
immediately analyzed using a FACS Calibur flow cyto-
meter (Becton Dickinson, FACS Calibur).
Animal models of unilateral renal IRI
All work involving animals was done in accordance with
the animal use protocol enacted by the Institutional Ani-
mal Care and Use Committees of School of Medicine,
Shanghai Jiao Tong University. All animals used were
male SD rats (180 to 200 g), which were housed at a con-
stant temperature and humidity, with a 12:12-h light-dark cycle. Animal models were performed in male SD
rats (180 to 200 g) by left ischemia for 60 minutes,
Sham-treated animals were treated in a similar manner,
except that the renal vessels were not clamped. A total of
100 ug MVs in 1 mL of vehicle (M199, Gibco BRL Co.,
USA) or a total of 1 ml of vehicle only was administered
via caudal vein immediately after reperfusion. The ani-
mals were separated into different groups according to
different therapeutic procedures. We used at least six rats
for each group at different time points: 1) sham-treated
rats (n = 18); 2) vehicle-injected IRI rats (n = 18); MVs-
injected IRI rats (n = 18). The rats were sacrificed at 24 h,
48 h and 2 weeks, respectively. Blood and kidney samples
were collected and submitted for corresponding exami-
nation. To trace MVs in the kidneys, the PKH-26 dye
(Sigma) kit was used to label the MVs. Then, 100 ug of
PKH-26 labeled MVs were injected intravenously into
AKI rats, and the unlabeled MVs were used as a con-
trol. Rats were sacrificed after 3 h and kidneys were
acquired for frozen sectioning. The Cytokeratin 19 anti-
body (Abcam,) was used for staining the cytoplasm of tu-
bular epithelial cells; Hoechst 33258 dye (Sigma) was
added for nuclear staining.
Renal function
After the right uninjured kidneys of the rats were re-
moved on Day 12, blood samples were obtained for meas-
urement of plasma BUN and creatinine on Day 14. Serum
creatinine and BUN were measured by a Beckman
Analyzer II (Beckman Instruments, Inc.).
ELISA analyses of vWF levels in serum and cytokine
expression in injured kidneys
For analysis of the level of vWF in serum, samples were
frozen at -80°C until analysis and we used a Rat vWF
Elisa kit following the manufacturer’s instructions (Eiaab,
Hubei, China), and for analysis of TNF-α and IL-10 in
injured kidneys, samples were frozen at -80°C until ana-
lysis. We used a Rat TNF-α Elisa kit (R & D Systems
Inc., USA) and an IL-10 Elisa kit (R & D Systems, Inc.,
USA) following the manufacturer’s instructions.
Immunohistochemistry
One portion of the renal tissue was fixed in 4% parafor-
maldehyde and embedded in paraffin. Sections 4 um-
thick were labeled with mouse antibody to rat CD68
(dilution 1:100; Abcam), mouse antibody to rat α-SMA
(dilution 1:500; Abcam), rat antibody to human CX3CL1
(dilution 1:250; Abcam), rat antibody to human Ki67
(dilution 1:250; Abcam) followed by horseradish peroxide
(HRP)-conjugated secondary antibody using diaminoben-
zidine (DAB) reagents as substrates and then counter-
stained with hematoxylin. The numbers of CD68+ cells in
the corticomedullary junctions and outer medullas of
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power fields (HPF). Under 400× magnification, scoring for
Ki67-positive cells was carried out by counting the num-
ber of positive tubular cell nuclei in 30 random fields from
randomly chosen kidney sections for each animal (n = 6
rats, each group). Tubular cell apoptosis was assessed
by a TUNEL assay using an In Situ Cell Death Detec-
tion Kit (Roche, Mannheim, Germany). Kidney sec-
tions were screened for tubular cells of positive nuclei
under 400× magnification. The apoptotic score was
achieved by counting the number of positive nuclei in
30 random fields.Hematoxylin and Eosin (H&E) staining
To detect the injury to the kidneys, they were fixed in
4% paraformaldehyde (pH 7.4), gradually dehydrated, em-
bedded in paraffin, cut into 4-μM sections and stained
with H&E stain. Histopathology scoring was applied based
on a previous study in a blinded fashion [23]. The score
was given based on the grading of tubular necrosis,
loss of brush border, cast formation and tubular dila-
tation in 10 randomly chosen, non-overlapping fields
(200×) as follows: 0 (none), 1 (≤10%), 2 (11 to 25%),
3 (26 to 45%), 4 (46 to 75%), and 5 (≥76%).Masson’s trichromatic staining
The degree of interstitial fibrosis was scored semi-
quantitatively on a 0 to 3 scale (0, no lesion; 1, <33%
of parenchyma affected by the lesion; 2, 33% to 67%
of parenchyma affected by the lesion; 3, >67% of par-
enchyma affected by the lesion). The scores were
assessed by a blinded observer in 100 HPFs (magnifi-
cation 400×) of parenchyma for each rat (n = 6 rats, each
group). The total score was obtained by the addition of all
scores, with a maximum score of 300.Western blot
Protein concentration was measured with BCA Protein
Assay, 30 ug of total protein were electrophoresed on an
8% to 10% SDS-PAGE gel and then transferred onto
nitrocellulose membranes (Millipore, USA). Membranes
were blocked in 5% non-fat milk in TBS containing 0.1%
Tween 20 for 1 h at room temperature, and then each
membrane was incubated with a rabbit antibody to rat
CX3CL1 (dilution 1:1,000; Abcam), mouse antibody to
α-SMA (dilution 1:1,000; Abcam) or a GAPDH antibody
overnight at 4°C. After being washed in PBS, each mem-
brane was incubated for one to two hours with a se-
condary antibody conjugated by peroxidase at room
temperature, detected by ECL reagent (Millipore, USA).
The density of each band was analyzed by Image-Pro Plus
6.0 software.Immunochemistry staining for CX3CL1 expression
in HUVECs
HUVECs injured by hypoxia were incubated on chamber
slides and exposed to MVs or control medium for 48
hours. Subsequently, the slides were fixed in 4% parafor-
maldehyde and permeabilized with HEPES-250 Triton ×
100 buffer (Sigma). Rat antibody to human CX3CL1
(dilution 1:1,000; Abcam) was used as the primary
antibody. Harris hematoxylin was added for nuclear
counterstaining.
RNA extraction and micro-RNA profiling by real-time
quantitative PCR
Total RNA was isolated from hWJMSC-MVs by Trizol
(Invitrogen, Carlsbad, CA, USA) extraction method. To
increase the yield of small RNAs, the RNA was precipi-
tated overnight. RNA concentration and RNA integrity
were determined by capillary electrophoresis on an Agi-
lent 2100 Bioanalyzer (Agilent Technologies, Palo Alto,
CA, USA). At the time of the study, commercially avail-
able primers (designed and synthetized by BioTNT,
Shanghai, China) were available for six mature human
micro-RNAs (miR-15a, miR-15b, miR-16, miR-195, miR-
424 and miR-497). We used these looped primers to
profile six mature micro-RNAs by real-time PCR using
an Applied Biosystems’ 7900HT real-time PCR instru-
ment. RNA was converted to cDNA by priming with a
mixture of looped primers (designed and synthetized by
BioTNT, Shanghai, China) using previously published
reverse transcription conditions [25]. Each RT reaction
contained 1 ug of total RNA, and real-time PCR was
performed using standard conditions.
Statistical analysis
Results from at least three independent experiments are
reported as the means ± standard deviation (SD). Statis-
tical analyses were performed using SPSS v19.0. A value
of P <0.05 was considered to be statistically significant.
Results
Isolation and expansion of hWJMSCs
hWJMSCs were isolated and identified as our group pre-
viously showed [23]. Briefly, the cells had a spindle-shaped
morphology and adhered to plastic surfaces. With FACS
analysis, we found that the expression of MSC markers
(CD44, CD73, CD90 and CD105) was positive, whereas
the expression of hematopoietic markers (CD45, CD34
and CD14) and an endothelial marker (CD31) was nega-
tive [23]. In addition, these cells harbored the potential to
differentiate toward chondrocytes and osteoblasts [23].
Isolation and characterization of HUVECs
HUVECs were isolated from umbilical cord vein by
collagenase digestion successfully. Immunofluorescence
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VE-Cadherin.
Extraction and characterization of hWJMSC-MVs
hWJMSC-MVs were successfully isolated and character-
ized as we previously described [24]. They were hetero-
geneous lipid bilayer vesicles of approximately 30 to
500 nm in diameter, and characterized as cup-shaped
or irregular-shaped (Figure 1A). FACS analysis showed
hWJMSC-MVs were positive for some surface-expressed
molecules typically expressed by hWJMSCs, such as
CD9, CD44, CD63 and CD73 and negative for CD34
and CD45 [24].Figure 1 hWJMSC-MVs observed by transmission electron microsco
heterogeneous lipid bi-layer vesicles that range from 30 to 500 nm in
bar = 1 um). (B) Representative micrographs of renal histology at 48 h
(Original magnification 200×. Scale bar = 50 um). (C) Histopathological
group and vehicle, sham versus vehicle group, MVs versus sham group
**P <0.05, sham versus MVs). (D) vWF in plasma was increased at 24 h
is a significantly decreased vWF level in 24 h and 48 h compared with
of six serum samples for each experimental condition. (n = 6. *P <0.05,
sham versus MVs). AKI, acute kidney injury; hWJMSC, human Wharton-J
MVs, microvesicles.The alleviation of I/R-induced kidney injury by
hWJMSC-MVs in early stages
To evaluate the tubular injury level, H&E staining was
performed. Lesions were observed in rats at 48 h by
H&E staining of kidney tissue slices. The slices showed
that numerous necrotic areas of the proximal epithe-
lium had appeared and abundant tubular protein casts
had formed in the vehicle and MVs therapy groups.
However, the tubular lesions obviously decreased in
the MV group compared to the vehicle (Figure 1B).
The representation of histological score suggested the
same results (Figure 1C). Circulating vWF was measured
as a marker of endothelial injury. The serum level ofpy and effects in IRI induced AKI in rats. (A) hWJMSC-MVs were
diameter, and were characterized by cup-shaped morphology (Scale
after reperfusion, in sham-operated rats and in MVs rats or vehicle
scoring shows a significant difference between the MV-treated
(n = 6. *P <0.05, sham versus vehicle, #P <0.05, MVs versus vehicle,
and 48 h, respectively, after IRI. However, in the MVs group, there
the vehicle group. All quantitative data are shown as mean ± SD
sham versus vehicle; #P <0.05, MVs versus vehicle, **P <0.05,
elly mesenchymal stem cells; IRI, ischemia/reperfusion injury;
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sham, after IRI (respectively, 42.13 ± 2.34 ng/ml versus
18.19 ± 1.06 ng/ml, P <0.05, and 56.25 ± 3.42 ng/ml
versus 18.19 ± 1.06 ng/ml, P <0.05). Surprisingly, in
the MV group there was a significant reduction of the
vWF level at 24 h and 48 h compared with the ve-
hicle group (respectively, 31.18 ± 0.95 ng/ml versus
42.13 ± 2.34 ng/ml P <0.05, and 37.70 ± 2.61 ng/ml
versus 56.25 ± 3.42 ng/ml, P <0.05). Compared with
the sham group, the MV group still had a high level
(respectively, 31.18 ± 0.95 ng/ml versus 18.19 ± 1.06 ng/ml,
P <0.05, and 37.70 ± 2.61 ng/ml versus 18.19 ± 1.06 ng/ml,
P <0.05), which is shown in Figure 1D. Three hours
after PKH-26-labeled MVs (red fluorescence) were in-
jected intravenously, red fluorescence was observed in
the kidneys of the AKI rats, while there was no red
fluorescence detected in the control group (Additional
file 1: Figure S1).Figure 2 Effects of hWJMSC-MV administration on the proliferation a
of Ki67 and TUNEL immunostaining in the injured kidneys at 48 h after reperf
(B) Quantification of TUNEL-positive tubular epithelium cells in the kidney sec
*P <0.05, sham versus vehicle; #P <0.05, MVs versus vehicle, **P <0.05, sham v
the kidney sections at different time points after reperfusion with hWJMSC-M
**P <0.05, sham versus MVs).hWJMSC-MVs mitigated the apoptosis and enhanced the
proliferation of renal cells
As shown in Figure 2, the number of TUNEL-positive cells
in the vehicle and MV groups significantly increased at
24 h and 48 h after IRI compared to the sham group (re-
spectively, 14.8 ± 5.0 versus 2.2 ± 0.8, P <0.05 and 12.8 ± 3.0
versus 2.2 ± 0.8, P <0.05; 6.9 ± 1.7 versus 2.2 ± 0.8, P <0.05
and 6.1 ± 1.5 versus 2.2 ± 0.8, P <0.05), while the kidneys of
hWJMSC-MV-treated rats exhibited fewer TUNEL-positive
cells than the vehicle group (24 h and 48 h, respectively,
6.9 ± 1.7 versus 14.8 ± 5.0, P <0.05; 6.1 ± 1.5 versus 12.8 ±
3.0 P <0.05). The number of Ki67-positive cells in the
vehicle and MV groups significantly increased at 24 h
and 48 h after IRI was compared to the sham group
(respectively, 26.6 ± 4.7 versus 5.4 ± 2.3 P <0.05; 37.9 ± 11.2
versus 5.4 ± 2.3, P <0.05; 63.8 ± 13.0 versus 5.4 ± 2.3 P <0.05;
65.3 ± 15.0 versus 5.4 ± 2.3, P <0.05). Meanwhile, after being
treated with hWJMSC-MVs, the number of proliferatingnd apoptosis of tubular epithelium cells. (A) Representative images
usion treated with hWJMSC-MVs (magnification 200×, Scale bar = 50 um).
tions at different time points after reperfusion with hWJMSC-MVs. (n = 6,
ersus MVs). (C) Quantification of Ki67-positive tubular epithelium cells in
Vs. (n = 6, *P <0.05, sham versus vehicle; #P <0.05, MVs versus vehicle,
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vehicle treatment (respectively, 26.6 ± 4.7 versus 63.8 ± 13.0,
P <0.05; 37.9 ± 11.2 versus 65.3 ± 15.0, P <0.05).
IRI-induced fibrosis is abrogated by MVs therapy, as well
as improvement of renal function in late stage
At two weeks post-IRI, the exposure to IRI led to the de-
velopment of significant fibrotic lesions in the renal
interstitial area, as indicated by Masson’s tri-chrome
staining. In contrast, after MVs therapy there was only a
slight fibrogenesis (Figure 3A,B). In addition, α-SMA
expression on tubular cells, an indicator of epithelial-
mesenchymal transition, occurred mostly in vehicle-
treated animals and slightly in MVs infusion rats (Figure 4).
Furthermore, after the right uninjured kidney was re-
moved on Day 12, the level of serum creatinine in animals
receiving vehicle infusion was significantly higher than
that of sham and MV infusion on Day 14 (vehicle versus
MVs, 8.30 ± 0.37 versus 4.32 ± 2.10 mg/mL, P <0.05; ve-
hicle versus sham, 8.30 ± 0.37 versus 4.12 ± 0.59 mg/mL,
P <0.05), there is no difference in 24 h and 48 h without
the removal of the right uninjured kidney (Figure 3C). A
similar result was observed when BUN in plasma wasFigure 3 hWJMSC-MVs alleviate the renal fibrosis in injured kidney tissu
micrographs of Masson’s tri-chrome staining in tubular interstitial areas. Ischem
deposition, whereas the MVs group had a remarkable reduction in collagen d
Fibrosis score. The highest fibrosis score was achieved by the vehicle group, w
obtained by the addition of all scores for collagen staining from 30 random h
are shown as mean ± SD of six kidney samples for each experimental conditio
**P <0.05, sham versus MVs). (C, D) Serum creatinine and BUN levels were me
groups. The right uninjured kidneys of rats were removed on Day 12, and
of data with six animals in each group (n = 6, *P <0.05, sham versus vehic
MSCs derived microvesicles.assessed (vehicle versus MVs, 43.81 ± 5.20 versus 25.72 ±
3.52 mg/mL, P <0.05; vehicle versus sham, 43.81 ± 5.20
versus 21.91 ± 5.78 mg/mL, P <0.05) (Figure 3D).
The hWJMSC-MVs infusion reduced the infiltration of
macrophages and attenuated inflammation in early stage
The immunohistochemistry (IHC) of CD68 showed the
expression of macrophages in injured kidney tissues. The
IRI rat kidney had a greater number of CD68-positive
macrophages than the Sham at 24 h, 48 h and 2 weeks (re-
spectively, 52.6 ± 3.1 versus 2.0 ± 0.8 P <0.05; 64.4 ± 2.0
versus 2.0 ± 0.8 P <0.05; 36.2 ± 1.7 versus 2.0 ± 0.8 P <0.05;
26.1 ± 4.4 versus 2.0 ± 0.8 P <0.05; 38.2 ± 2.8 versus 2.0 ±
0.8 P <0.05; 33.6 ± 1.9 versus 2.0 ± 0.8 P <0.05, per high-
powered field 400×), while compared to the vehicle, MVs
treatment significantly decreased the infiltration at 24 h
and 48 h (respectively, 26.1 ± 4.4 versus 52.6 ± 3.1 P <0.05;
38.2 ± 2.8 versus 64.4 ± 2.0 P <0.05; per high-powered field
400×). However, two weeks after reperfusion, there was
no significant difference between the vehicle group and
MV group (vehicle versus MVs, 36.2 ± 1.7 versus 33.6 ±
1.9, per high-powered field 400×) (Figure 5A,B). Mean-
while, the ELISA analysis of IL-10, an anti-inflammationes and improve renal functions after two weeks. (A) Representative
ic injury caused a progressive increase in positive-staining collagen
eposition. (The original magnification is 400×, Scale bar = 50 um). (B)
hereas the MV group had a significantly lower score. The score was
igh power fields with a maximum score of 300. All quantitative data
n. (n = 6, *P <0.05, sham versus vehicle; #P <0.05, MVs versus vehicle,
asured at the indicated times after injury in the sham, vehicle and MVs
serum samples collected at different times. Values are the mean ± SD
le; #P <0.05, MVs versus vehicle). hWJMSC-MVs, human Wharton-Jelly
Figure 4 hWJMSC-MVs reduce the α-smooth muscle actin (α-SMA) expression in kidney tissues. (A) Representative micrographs illustrating
α-smooth muscle actin (α-SMA) expression in kidney tissues, In comparison with MVs group, the vehicle group exhibited stronger positive staining
for α-SMA in kidney tissue sections at two weeks (the original magnification is 400×, Scale bar = 50 um). (B, C) α-SMA expression in kidney tissues
was measured by Western blot analysis, and MVs dramatically reduce the α-SMA expression, all quantitative data are shown as mean ± SD of three
experimental conditions (n = 3, *P <0.05, sham versus vehicle; #P <0.05, MVs versus vehicle).
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elevated level after MV treatment at 24 h and 48 h
(sham versus vehicle 213 ± 106 versus 1,317 ± 193 pg/mg
P <0.05; 213 ± 106 versus 617 ± 63 pg/mg, P <0.05; MVs
versus vehicle 2,460 ± 478 versus 1,317 ± 193 pg/mg,
P <0.05; 1,398 ± 435 versus 617 ± 63 pg/mg, P <0.05)
(Figure 5C). In contrast, the pro-inflammation factor
TNF-α level in kidney tissues was lowered by MVs
at 24 h and 48 h (sham versus vehicle, 4.7 ± 1.6 ver-
sus 38.3 ± 17.3 pg/mg, P <0.05; 4.7 ± 1.6 versus 36.6 ±
3.1 pg/mg, P <0.05; MVs versus vehicle, 16.4 ± 5.2 versus
38.3 ± 17.3 pg/mg, P <0.05; 14.7 ± 2.1 versus 36.6 ±
3.1 pg/mg, P <0.05) (Figure 5D).
The down-regulated expression of CX3CL1 by MVs both
in vivo and in vitro
The suppression effect of MVs on CX3CL1 was shown
by IHC as well as the Western blot analysis method. As
shown in Figure 6A-C, the CX3CL1 protein in the in-
jured kidney was up-regulated compared with the shamgroup, but down-regulated at 24 h and 48 h after MV
intervention. There was a similar observation in IHC re-
sults, which locate CX3CL1 protein at endothelial cells
in glomerulus and vessels. In order to confirm the effects
in vitro, we also performed Western blot and immunocyto-
chemistry on HUVEC under the hypoxia-injured model.
The results indicated the same as in vivo (Figure 6D-F).
HUVEC, Human umbilical vein endothelial cells; IHC, im-
munohistochemistry; MVs, microvesicles.
Profiling of CX3CL1 related micro-RNAs in hWJMSC-MVs
by real-time quantitative PCR
In order to investigate whether some micro-RNA con-
tained in the MVs played a role, we searched CX3CL1 in
the TargetScan database (version 6.2) and identified six
putative micro-RNA (miR-15a, miR-15b, miR-16, miR-
195, miR-424 and miR-497) targets to CX3CL1 mRNA
by matching the seed regions of each. The real-time
quantitative PCR analysis indicated that there were rela-
tively high levels of miR-15a, miR-15b and miR-16
Figure 5 Effects of hWJMSC-MVs on macrophage recruitment and the cytokine expression in injured kidneys. (A) Representative images
of interstitial macrophages labeled with CD68 in the kidney on 24 h, 48 h and 2 weeks after reperfusion (the original magnification is 400×, Scale
bar = 50 um). (B) Quantification of CD68+ macrophages/HPF in the kidney sections at different time points after reperfusion, all quantitative data
are shown as mean ± SD of six kidney samples for each experimental condition (n = 6, *P <0.05, sham versus vehicle; #P <0.05, MVs versus vehicle;
**P <0.05, sham versus MVs) (C) ELISA analysis of the anti-inflammatory cytokine IL-10 in injured kidney at 24 h and 48 h after reperfusion,
(n = 3, #P <0.05, MVs versus vehicle). (D) ELISA analysis of the TNF-α in the injured kidney at 24 h and 48 h after reperfusion. All data are
shown as mean ± SD of three kidney samples for each experimental condition. (n = 3, #P <0.05, MVs versus vehicle). HPF, high power fields;
hWJMSC-MVs, human Wharton-Jelly MSCs derived microvesicles.
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miR-195, miR-424 and miR-497 (Figure 7B). The same
results were seen in hWJMSCs (Figure 7A).
Discussion
In the present study, we observed that a single adminis-
tration of hWJMSC-MVs immediately after induction of
IRI could decrease the expression of CX3CL1 in the kid-
ney and lessen the infiltration of CD68+ macrophages at
the 24 h and 48 h time points after the reperfusion.
Meanwhile, the blood vWF level, a parameter reflecting
the injury to endothelial cells, declined and the apoptosis
of renal cells mitigated in the early stage of renal IRI.
Furthermore, the renal function was ameliorated and
kidney fibrosis was abrogated by MVs in the late stage.
In recent years, strategies for administration of stem
cells from various sources, such as bone marrow, fetal
membrane and adipose, for repairing kidney injury have
been reported [26-28], but the potential mechanismsremain unclear. In previous studies, Caplan et al. have
suggested that MSCs may provide a paracrine support
for kidney repair [17]. Consistently, Bi et al. demons-
trated that the administration of conditioned medium
from MSCs may also have beneficial effects on AKI [20],
indicating that endocrine or paracrine mechanisms play
an important role. Our group also found that hWJMSCs
could alleviate acute and chronic kidney injury through
an endocrine mechanism [29]. MVs, which are contained
in the condition medium of MSCs, are small vesicles re-
leased by cells bearing the surface antigens characteristic
of the original cells. They can also enter the target cells
through specific receptor ligand interactions and transfer
micro-RNA, mRNA, proteins and other bioactive mate-
rials [21,30-32]. Bruno et al. demonstrated a protective
effect of bone marrow MSC-derived MVs on acute kid-
ney injury and found that MVs could be detected in an
injured kidney after intravenous administration [21]. In
the present study, we isolated MVs from hWJMSC-
Figure 6 Effects of hWJMSC-MVs administration on expression of CX3CL1 in injured kidney in vivo and HUVECs in vitro. (A) IHC localization
of CX3CL1 in the kidney 48 h after IRI. CX3CL1 was mainly expressed on endothelial cells (arrow points to positively stained endothelial cells; the
original magnification is 200×, Scale bar = 50 um). (B, C) CX3CL1 expression in kidney tissues was measured by Western blot analysis, and MVs
dramatically decreased the CX3CL1 expression. Data are expressed as mean ± SD of three experiments (n = 3, *P <0.05, sham versus vehicle; #P <0.05,
MVs versus vehicle; **P <0.05, sham versus MVs). (D) ICC of CX3CL1 in HUVECs 48H after hypoxia injury (the original magnification is 200×, Scale
bar = 50 um). (E, F) CX3CL1 expression in HUVECs was measured by Western blot analysis, and MVs dramatically decreased the CX3CL1 expression
both in 24 h and 48 h after hypoxia. Data are expressed as mean ± SD of the three experiments (n = 3, *P <0.05, sham versus vehicle; #P <0.05, MVs
versus vehicle). hWJMSC-MVs, human Wharton-Jelly mesenchymal stem cell derived microvesicles; IHC, immunohistochemistry; MVs, microvesicles.
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and found that hWJMSC-MVs have a crucial therapeutic
effect in AKI.
To investigate the potential mechanisms of MVs in the
IRI, we detected the CD68+ macrophages in the in-
jured kidney. We found that the expression of CD68+macrophages as well as the serum level of vWF in
the MVs group declined at 24 h and 48 h after reper-
fusion. Macrophages’ effects on tissue repair depend on
their phenotypes and the inflammatory milieu [33,34].
Some strategies to block the initial inflammatory response,
such as depleting macrophages or inhibiting the action of
A B
MVs
Figure 7 Representative quantitative reverse transcriptase qRT-PCR for CX3CL1 related micro-RNAs in hWJMSCs and hWJMSC-MVs.
(A, B) qRT-PCR analysis of CX3CL1 related micro-RNAs in hWJMSCs and hWJMSC-MVs, data show that both the hWJMSCs and hWJMSC-MVs
contain relatively high levels of miR-16, miR-15b and miR-15a, and low levels or no miR-195, miR-424 and miR-497. Each experiment was repeated
three times. hWJMSC-MVs, human Wharton-Jelly mesenchymal stem cell derived microvesicles; MVs, microvesicles.
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AKI [9,33]. In our study we found CD68+ macrophages
were reduced significantly by MVs in the early stage of
AKI. Inflammatory cytokines are known to play an im-
portant role in ischemic AKI; the decreased expression of
TNF-α and increased expression of IL-10 in the injured
kidney was also observed. Moreover, the renal cell apop-
tosis was mitigated and proliferation was enhanced
in the MV group. From the data above, we confirmed
that hWJMSC-MVs play a therapeutic role in I/R-
induced acute kidney injury through the regulation
of inflammation.
To further study the potential mechanisms, we eval-
uated the expression of CX3CL1, which is a potent
chemo-attractant protein for macrophages. We found
that the expression of CX3CL1 was up-regulated obvi-
ously in the kidney after ischemic AKI, which is in ac-
cordance with the published data [13,16]. Interestingly,
in the MV group, the CX3CL1 was dramatically down-
regulated in the injured kidney. Further, in in vitro
studies, we also found that MVs could suppress the ex-
pression of CX3CL1 in cultured HUVECs under a
hypoxia-oxygen injury model. On the other hand, previ-
ous studies show that CX3CL1 with its cognate receptor
CX3CR1 could mediate the immune cell adhesion in
the pathogenesis of vascular injury [35,36]; the authors
also found that the expression of CX3CL1 protein in
the kidney increased markedly in ischemic AKI and
that CX3CL1/CX3CR1 promotes kidney injury both
in hypertensive and ischemic animal models [15,16].
Meanwhile, inhibition of CX3CR1, the only known re-
ceptor of CX3CL1, could reduce the macrophages in
an injured kidney and have therapeutic effects in AKI
[14,16]. Thus, we concluded that down-regulation of
CX3CL1 by MVs might be a way to reduce the infiltration
of macrophages in the kidney and MVs’ inflammation
regulation property may be one of the underlying mecha-
nisms of hWJMSC-MVs’ therapeutic effects.It has also been shown that RNA, including mRNA
and micro-RNA, contained in the MVs could be trans-
ferred into the target cells and may play an important
role in the repair of I/R-induced AKI [31]. Recently,
some studies also found that different cell-derived MVs
protect against acute kidney injury via a horizontal trans-
fer of related mRNAs or micro-RNAs [21,37]. Thus,
we supposed that some secreted patterns of micro-
RNAs, which can modulate the expression of CX3CL1,
may be included in the hWJMSCs-MVs. Moreover, it
has also been reported that some micro-RNAs pre-
dicted by the Targetscan Database for particular mol-
ecule was confirmed [38]. So we paid more attention to
miR-15a, miR-15b, miR-16, miR-195, miR-424 and miR-
497, which are the targeted results for CX3CL1 in the
Targetscan Database. This means these micro-RNAs are
the biological target molecules and, by matching the
CX3CL1 to the seed region, may have the potential ef-
fects of modulation of CX3CL1. Interestingly, the miR-16,
miR-15b and miR-15a were profiled successfully both in
hWJMSCs and hWJMSC-MVs by the real-time quantita-
tive PCR method with a high concentration, and we think
that these micro-RNAs contained in MVs may involve the
modulation of CX3CL1 expression. However, how MVs
modulate the expression of CX3CL1 and whether these
micro-RNAs have functional effects are unknown. We
plan to investigate the deeper mechanism in our next
project.Conclusions
A single administration of hWJMSC-MVs immediately
after IRI could ameliorate kidney ischemia/reperfusion
injury both in the acute and chronic stages, and it could
also suppress the expression of CX3CL1 and mitigate
the inflammation levels in injured kidneys in the early
stage, which may be regarded as a novel mechanism for
therapeutic effects on ischemic AKI.
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Additional file 1: Figure S1. Distribution of hWJMSC-MVs after injection.
Representative confocal micrographs of frozen tissue sections of rats
injected with PKH26-labeled MVs (red) kidneys. Red fluorescence (white
arrows) was observed in the kidneys after injection of PKH26-labeled MVs at
3 h. Tubular epithelial cell cytoplasm and nuclei were stained green and
blue, respectively. (Original magnification 200 ×).
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